Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H8MH
|
|||
| Former ID |
DIB008834
|
|||
| Drug Name |
HGH-CTP
|
|||
| Synonyms |
MOD-401; MOD-4023; Human growth hormone (injectable, CTP, growth disorder), Modigene; Long-acting hGH (injectable, CTP, growth disorder), Modigene
Click to Show/Hide
|
|||
| Indication | Growth hormone deficiency [ICD-11: 5A61.3] | Phase 3 | [1] | |
| Company |
Prolor biotech; chiasma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatotropin (GH1) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Reactome | Prolactin receptor signaling | |||
| Growth hormone receptor signaling | ||||
| WikiPathways | Endochondral Ossification | |||
| Prolactin receptor signaling | ||||
| Growth hormone receptor signaling | ||||
| Adipogenesis | ||||
| Synthesis, Secretion, and Deacylation of Ghrelin | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01909479) A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency. U.S. National Institutes of Health. | |||
| REF 2 | Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.